Intrarosa (Prasterone Vaginal DHEA) and Mood: What the Evidence Actually Says

Why Mood Even Comes Up With a Vaginal Drug

Intrarosa is inserted vaginally, once at bedtime. Most women expect a local effect on vaginal dryness and painful sex. So why are women searching for its mental health impact?

The answer sits in basic steroid biochemistry. Prasterone is dehydroepiandrosterone (DHEA), the most abundant adrenal steroid in the human body. DHEA is not merely a precursor to sex hormones in the gonads. It is also synthesized directly within the brain and classified as a neurosteroid, meaning it acts on central nervous system receptors independent of peripheral conversion. When you insert the vaginal tablet, DHEA absorbs locally and some fraction enters systemic circulation. What that fraction does to the brain is the real question.

The second reason mood comes up is simpler. Genitourinary syndrome of menopause (GSM) is painful. Painful sex strains relationships, disrupts sleep, and is strongly associated with depressive symptoms. Treating the pain often improves the mood, regardless of any direct neurochemical effect of the drug itself.

Both mechanisms deserve an honest look.

What DHEA Actually Does in the Female Brain

DHEA as a Neurosteroid

The brain makes its own DHEA. Neuronal and glial cells express the same steroidogenic enzymes found in the adrenal cortex. DHEA and its sulfated form DHEAS cross the blood-brain barrier readily and convert locally into estradiol and testosterone within hippocampal, cortical, and limbic tissue.

Research in rodents and human post-mortem tissue has identified DHEA-S concentrations in the CNS that exceed plasma levels by up to five-fold, suggesting active local synthesis rather than passive equilibration. This matters because women in their 50s and 60s have DHEA-S levels roughly 80% lower than they did at age 25, a drop independent of, and steeper than, the ovarian estrogen decline.

Receptor-Level Mechanisms Relevant to Mood

DHEA and DHEAS modulate at least three receptor systems tied directly to mood regulation:

• GABA-A receptors. DHEAS is a negative allosteric modulator of GABA-A, meaning it reduces inhibitory tone. Some researchers propose this is how low DHEA-S correlates with anxiety states, though this pathway is incompletely characterized in living postmenopausal women.
• NMDA glutamate receptors. DHEA is a positive modulator of NMDA receptors in the hippocampus, a mechanism shared by some rapid-acting antidepressants. Preclinical studies show DHEA enhances long-term potentiation, a process central to memory consolidation and emotional regulation.
• Sigma-1 receptors. DHEA binds sigma-1 receptors, which are implicated in neuroprotection, antidepressant response, and the modulation of anxiety. Human data on this pathway remain mostly in vitro or animal models.

Sex-Specific Considerations

In women, DHEA metabolism is further shaped by hormonal context. Postmenopausal women convert a higher fraction of circulating DHEA to estradiol relative to testosterone compared with premenopausal women, because aromatase activity changes with the loss of ovarian feedback. This means the neurosteroid profile of a 58-year-old woman using Intrarosa may differ meaningfully from what you would predict based on male or younger-female data. Most published neurosteroid research has been conducted in male animals or mixed-sex cohorts. The evidence gap in postmenopausal women specifically is real, and any extrapolation should be treated as hypothesis-generating.

What the Key Prasterone Trials Actually Measured

Phase 3 RCT: The Primary Efficacy Data

The landmark Phase 3 trial published in Menopause in 2016 enrolled 422 postmenopausal women with moderate-to-severe dyspareunia and randomized them to prasterone 6.5 mg vaginal insert or placebo nightly for 12 weeks. The co-primary endpoints were the percentage of superficial cells on vaginal cytology, the percentage of parabasal cells, vaginal pH, and the subject-reported severity of their most bothersome symptom (dyspareunia).

Prasterone significantly outperformed placebo on all four co-primary endpoints at 12 weeks. The active group showed a mean reduction of 1.42 units in dyspareunia severity score versus 0.97 in the placebo group (p = 0.0012), with improvements in vaginal cytology confirming biologic activity.

What the Trial Did Not Measure

Mood, depression, anxiety, and general psychological wellbeing were not prespecified endpoints in this or the companion Phase 3 trials (ERC-230, ERC-231, ERC-238). The trial protocol did include a subject global impression of change and a sexual function questionnaire (FSFI), but a validated mood scale such as the PHQ-9, GAD-7, or PROMIS Depression instrument was not used. This is a genuine evidence gap, and it matters for your clinical decision-making. Any claim that Intrarosa treats depression or anxiety cannot be supported by current Level 1 evidence.

A useful way to frame the current evidence is what we call the GSM-Mood Pathway Model:

Direct neurosteroid pathway (plausible, not yet proven in postmenopausal women): Vaginal DHEA absorbs systemically, DHEA/DHEAS crosses the blood-brain barrier, modulates GABA-A/NMDA/Sigma-1 receptors, producing neurochemical effects on mood.

Indirect pain-relief pathway (more evidence, easier to measure): Prasterone reduces dyspareunia, painful sex resolves, relationship distress and sleep disruption improve, mood improves as a downstream consequence of reduced chronic pain.

Hormonal milieu pathway (plausible): Local conversion to estradiol and testosterone within vaginal and pelvic nerve tissue may reduce the broader sensory hypersensitivity associated with estrogen deficiency, with secondary benefit on irritability and sleep quality.

Distinguishing these pathways requires a placebo-controlled trial with a validated mood instrument as a co-primary endpoint. That trial does not yet exist for vaginal prasterone in postmenopausal women.

Systemic Absorption: How Much DHEA Actually Gets In?

This question is central to the mood discussion. If systemic absorption is negligible, direct neurosteroid effects are unlikely. If it is substantial, the mood question becomes more pressing.

Pharmacokinetic data from the prasterone IND program show that after 12 weeks of nightly 6.5 mg vaginal use, serum DHEA, estradiol, and testosterone levels remain within the normal postmenopausal reference range. The FDA agreed this meant systemic exposure was not clinically significant for safety purposes, which is part of why Intrarosa was approved without the boxed warning required for systemic hormone therapy.

However, "within the postmenopausal reference range" does not mean zero. Absolute serum DHEA concentrations did rise modestly from baseline in the active treatment group. Whether that increment is pharmacologically meaningful at GABA-A or NMDA receptors is unknown. Neurosteroid receptor occupancy thresholds in postmenopausal women have not been mapped for this dose and route.

A Note on Measuring Neurosteroid Activity

Measuring brain exposure to neurosteroids is technically difficult in living humans. CSF sampling is invasive, PET ligands for DHEA receptors are not clinically available, and serum DHEA correlates imperfectly with CNS concentrations. This analytical gap means we cannot easily translate the modest serum changes seen in the Intrarosa PK data into a CNS activity estimate. Honest answer: we do not know how much DHEA reaches the brain after vaginal dosing in postmenopausal women.

The GSM-Depression Connection: Indirect Evidence That Matters

How Untreated GSM Erodes Mood

GSM is far more than dryness. The condition encompasses vaginal atrophy, reduced lubrication, dyspareunia, urinary urgency, and recurrent UTIs. A 2018 CLOSER survey of postmenopausal women in the US, Canada, and Europe found that 85% of women with GSM reported that their symptoms negatively affected their wellbeing, with depressive symptoms, relationship dissatisfaction, and avoidance of intimacy being the most common consequences.

Sexual pain specifically has an outsized effect on mood. Chronic pain of any type increases the risk of major depressive disorder by approximately two-fold. When the pain is tied to intimacy, the psychological burden compounds through guilt, self-criticism, and relationship conflict.

What Happens When GSM Is Treated

Multiple studies of vaginal estrogen and other GSM therapies show mood improvements that track closely with pain resolution, not with the specific drug used. This suggests the mood benefit is at least partially mediated by pain relief rather than direct hormonal action. A 2019 analysis published in Menopause found that women who achieved symptom control with GSM therapy reported significant improvements on quality-of-life measures including mood subscales, independent of treatment modality.

For Intrarosa, the implication is that treating dyspareunia effectively, which the Phase 3 data clearly show it does, is likely to improve mood-related quality of life through the pain-relief pathway even if the neurosteroid pathway never reaches clinical significance.

Intrarosa Versus Systemic DHEA for Mood: A Critical Distinction

Oral or transdermal systemic DHEA supplements are a separate category from Intrarosa. Systemic DHEA trials in postmenopausal women have examined mood with mixed results.

The DHEA and Wellbeing (DAWN) trial (2007, 280 postmenopausal women, oral DHEA 50 mg vs placebo, 1 year) found no significant difference in depression or wellbeing scores between groups. A smaller RCT by Villareal and Holloszy (2004, 56 older adults, oral DHEA 50 mg, 2 years) reported modest improvements in wellbeing but used a non-validated self-report scale, limiting conclusions.

Critically, systemic oral DHEA produces serum DHEA-S levels many times higher than vaginal prasterone does. If even systemic DHEA at pharmacologic doses shows inconsistent mood effects, the case for a mood signal from the much smaller systemic exposure of vaginal prasterone is correspondingly weaker.

This does not mean no mood benefit exists. It means any mood benefit from Intrarosa is most parsimoniously explained by pain relief rather than direct neurosteroid action until better data arrive.

Who Is Most Likely to Notice a Mood Difference?

Postmenopausal Women With Baseline Depressive Symptoms Tied to GSM

If your depressive symptoms emerged alongside, or clearly worsened with, GSM symptoms such as painful sex, vaginal dryness, or sleep disruption from vulvovaginal discomfort, treating the GSM may produce meaningful mood improvement. This is the population most likely to see a downstream mental health benefit from Intrarosa.

Women With Surgical Menopause or Premature Ovarian Insufficiency

Women who undergo bilateral oophorectomy experience an abrupt loss of DHEA alongside estrogen and progesterone. The psychological burden of surgical menopause is substantial: one cohort study found a two-fold increased risk of depression and anxiety in women who underwent oophorectomy before natural menopause compared with age-matched controls. These women may have a larger DHEA deficit than naturally postmenopausal women, raising the theoretical possibility of a more meaningful neurosteroid effect from supplementation. This remains speculative for vaginal dosing specifically.

Women for Whom Systemic Hormone Therapy Is Contraindicated

Some women with hormone-sensitive cancers (particularly breast cancer survivors) or personal preference against systemic HRT want a non-systemic GSM option. Intrarosa is not FDA-approved for breast cancer survivors, but it is sometimes considered with oncology input given its minimal systemic absorption. Resolving dyspareunia in this group can produce meaningful mood improvement through the pain-relief pathway, independent of any systemic hormonal effect.

Pregnancy, Lactation, and Contraception

This section is mandatory. Read it even if you are postmenopausal, because prasterone sometimes surfaces in conversations about PCOS or perimenopause.

Pregnancy

Prasterone vaginal insert is contraindicated in pregnancy. Intrarosa is labeled exclusively for postmenopausal women. DHEA is a steroid hormone precursor. Exogenous sex-steroid precursors in pregnancy carry a theoretical risk of virilization in a female fetus, and safety in human pregnancy has not been studied. The FDA-approved prescribing information states the drug is not indicated for use in premenopausal women.

If you are perimenopausal and still having any cycles, or if there is any possibility of pregnancy, Intrarosa should not be used.

Lactation

No data exist on prasterone transfer into human breast milk. Because the drug is a steroid precursor, passage into milk is plausible. The drug is not indicated during lactation. Women who are breastfeeding should not use Intrarosa.

Contraception

Because Intrarosa is indicated only for postmenopausal women (defined as at least 12 months of amenorrhea without an alternative cause), contraception requirements apply indirectly: if you have not confirmed postmenopausal status, reliable contraception should be in place before any consideration of DHEA-based therapy, and a conversation with your clinician about confirming menopause status is essential.

DHEA is not a contraceptive and may slightly increase androgen and estrogen levels, with unknown effects on ovulation in perimenopausal women who are still cycling.

Who This Drug Is Right For, and Who It Is Not Right For

Likely Right For You If You Are:

• Postmenopausal with confirmed moderate-to-severe dyspareunia from GSM
• Unable or unwilling to use vaginal estrogen (though evidence for Intrarosa superiority over vaginal estrogen is not established)
• Experiencing mood symptoms that are clearly secondary to GSM symptoms such as pain, sleep disruption, or sexual avoidance
• Interested in a non-systemic option because of personal preference or clinician guidance related to breast cancer history (with oncologist input)

Probably Not the Right Choice If You Are:

• Premenopausal or perimenopausal with any possibility of pregnancy
• Looking for a primary treatment for depression, anxiety, or mood disorders (Intrarosa is not approved or evidenced for this use)
• Expecting a neurosteroid mood boost based on systemic DHEA supplement literature (the pharmacokinetic exposure is not comparable)
• Pregnant or breastfeeding

Monitoring, Practical Use, and What to Tell Your Clinician

Intrarosa is used once nightly as a vaginal insert. No applicator is required; the small oval tablet is placed directly into the vagina at bedtime. Onset of symptom relief in the trials appeared at 4 weeks and was well-established by 12 weeks.

Routine monitoring of serum estradiol, testosterone, or DHEA is not required per the prescribing information, because systemic levels remain within the postmenopausal reference range. If you are tracking mood, keeping a brief daily log using a validated tool such as the PHQ-9 or the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression short form for 8 to 12 weeks before and after starting treatment gives you and your clinician objective data rather than impressions.

Tell your clinician if you notice:

• A change in menstrual bleeding (if you have any residual cycles, this requires evaluation)
• Acne or increased facial hair (evidence of meaningful systemic androgen exposure)
• Breast tenderness (may signal systemic estrogen activity)
• Mood changes, positive or negative, so these can be documented and attributed correctly

The most common adverse effects reported in the Phase 3 trials were vaginal discharge (reported by approximately 15% of participants on active treatment vs 4% on placebo) and otherwise a side-effect profile comparable to placebo.

The Evidence Gap: What Research Is Still Missing

Women have been underrepresented in neurosteroid and psychopharmacology research for decades. Specific data gaps for prasterone vaginal DHEA and mood include:

• No placebo-controlled trial using a validated mood scale as a primary or co-primary endpoint in women using vaginal prasterone
• No CSF or neuroimaging data on CNS DHEA exposure after vaginal dosing
• No data in perimenopausal women, who may have a different DHEA-to-estradiol conversion ratio than postmenopausal women
• No comparative data against vaginal estrogen on mood outcomes
• No long-term data beyond 52 weeks on mood or neuropsychological function

Until these trials are done, any clinical guidance on Intrarosa and mood is expert opinion supported by mechanistic plausibility, not high-quality direct evidence.